[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Bio-Signal Group Corp.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":98},{"warningLetters":4,"total":97},[5,32,54,76],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":27,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":19,"reference_number":19,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},2165,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2023-03-14T13:20:00Z\">03\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-19T05:00:00Z\">01\u002F19\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fb-j-group-641099-01192023\">B &amp; J Group\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations I","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Tilghman B. Frey\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Operating Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>B &amp; J Group\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1001 New Ford Mill Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Morrisville\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>19067\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 641099\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 19, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Frey:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products, including consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers). FDA has reviewed the records you submitted in response to our January 25, 2022 and February 9, 2022 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 374(a)(4)) for your facility, B &amp; J Group, FEI 3010096700, at 1001 New Ford Mill Road, Morrisville, Pennsylvania.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs as described in your response to our 704(a)(4) request do not conform to CGMP regulations, your drug products are deemed adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B))\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>704(a)(4) Request for Records and Related CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and (b))\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your response to our request for records and other information under section 704(a)(4) indicated that you are a contract filler of OTC hand sanitizer drug products and that you did not test the finished drug products before release. Specifically, in response to our request to provide the finished product specifications and test methods for both analytical and microbiological tests for each hand sanitizer product manufactured for distribution in the United States, you stated that this is “Done by customer” and “We just filled the bottles.”\u003C\u002Fp>\n\n\u003Cp>Owners and contract manufacturing facilities are both responsible for CGMPs, which includes the implementation of oversight and controls over the manufacture of drugs to ensure quality, including managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products.\u003C\u002Fp>\n\n\u003Cp>Full release testing, including for identity, strength, and impurities, must be performed prior to drug release and distribution. Without adequate testing, there is no scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision:\u003Cbr>\n&nbsp; o An action plan and timelines for conducting full chemical and microbiological testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; o A summary of all results obtained from testing reserve samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the records and information you provided, you did not demonstrate adequate testing of the identity of incoming components used in the manufacture of your drug products. Specifically, your response stated that raw material identity testing for each lot of each component is “Not Applicable,” testing of ethanol or isopropyl alcohol and methanol is “Done by each customer,” and testing the potency (assay) of ethanol or isopropyl alcohol used for hand sanitizer is “Not Applicable.”\u003C\u002Fp>\n\n\u003Cp>You manufacture multiple drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19)\u003C\u002Fem> at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the information you provided, you did not demonstrate that your manufacturing processes are reproducible and controlled to yield a product of uniform character and quality. For example, we asked you to provide a copy of the most recent, completed batch production record for each hand sanitizer product manufactured. You stated in your response that batch production records are “Maintained by customers.”\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003Cbr>\n• A list of all batches of any hand sanitizer drug products distributed by your firm, and a full reconciliation of all material you distributed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov and CDER-OC-OMQ-Communications@fda.hhs.gov. Please also identify your response with FEI 3010096700.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u002F District Director\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nOPQO Division I \u002F New Jersey District\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>\u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong>\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times. This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the&nbsp;guidance. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). Because B &amp; J Group hand sanitizer drug products were not prepared under the circumstances described in this guidance, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Tilghman B. Frey\n\nRecipient Title\n\nChief Operating Officer\n\nB & J Group\n\n1001 New Ford Mill Rd.\n\nMorrisville, PA 19067\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter 641099\n\nJanuary 19, 2023\n\nDear Mr. Frey:\n\nYour facility is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products, including consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers). FDA has reviewed the records you submitted in response to our January 25, 2022 and February 9, 2022 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 374(a)(4)) for your facility, B & J Group, FEI 3010096700, at 1001 New Ford Mill Road, Morrisville, Pennsylvania.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs as described in your response to our 704(a)(4) request do not conform to CGMP regulations, your drug products are deemed adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B))1.\n\n704(a)(4) Request for Records and Related CGMP Violations\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and (b))\n\nYour response to our request for records and other information under section 704(a)(4) indicated that you are a contract filler of OTC hand sanitizer drug products and that you did not test the finished drug products before release. Specifically, in response to our request to provide the finished product specifications and test methods for both analytical and microbiological tests for each hand sanitizer product manufactured for distribution in the United States, you stated that this is “Done by customer” and “We just filled the bottles.”\n\nOwners and contract manufacturing facilities are both responsible for CGMPs, which includes the implementation of oversight and controls over the manufacture of drugs to ensure quality, including managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products.\n\nFull release testing, including for identity, strength, and impurities, must be performed prior to drug release and distribution. Without adequate testing, there is no scientific evidence to assure that your drug products conform to appropriate specifications before release.\n\nIn response to this letter, provide:\n\n• A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision:\n\no An action plan and timelines for conducting full chemical and microbiological testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing reserve samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nBased on the records and information you provided, you did not demonstrate adequate testing of the identity of incoming components used in the manufacture of your drug products. Specifically, your response stated that raw material identity testing for each lot of each component is “Not Applicable,” testing of ethanol or isopropyl alcohol and methanol is “Done by each customer,” and testing the potency (assay) of ethanol or isopropyl alcohol used for hand sanitizer is “Not Applicable.”\n\nYou manufacture multiple drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19) at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload.\n\nIn response to this letter, provide:\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\n3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nBased on the information you provided, you did not demonstrate that your manufacturing processes are reproducible and controlled to yield a product of uniform character and quality. For example, we asked you to provide a copy of the most recent, completed batch production record for each hand sanitizer product manufactured. You stated in your response that batch production records are “Maintained by customers.”\n\nIn response to this letter, provide:\n\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\n• A list of all batches of any hand sanitizer drug products distributed by your firm, and a full reconciliation of all material you distributed.\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov and CDER-OC-OMQ-Communications@fda.hhs.gov. Please also identify your response with FEI 3010096700.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\u002F District Director\n\nU.S. Food and Drug Administration\n\nOPQO Division I \u002F New Jersey District\n\n________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). Because B & J Group hand sanitizer drug products were not prepared under the circumstances described in this guidance, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.","B & J Group","b-j-group-641099-01192023","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fb-j-group-641099-01192023","2026-10-26T08:08:00.033895+00:00","Warning Letter","Issued","2023-03-14","641099","Drugs","Division of Pharmaceutical Quality Operations I","Mr. Tilghman B. Frey","2026-08-20T01:12:01.995+00:00","VIA UPS and Electronic Mail","2023-01-19",{"id":33,"raw":34,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":19,"letter_url":46,"updated_at":47,"action_type":22,"case_status":23,"posted_date":48,"marcs_cms_no":49,"product_type":26,"closeout_date":19,"issuing_office":38,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},3217,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2021-08-10T13:20:00Z\">08\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-04T04:00:00Z\">08\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbbc-group-limited-614659-08042021\">BBC Group Limited\u003C\u002Fa>","Center for Drug Evaluation and Research","CGMP\u002FFinished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\n","CGMP\u002FFinished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Alan Wong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BBC Group Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Yangxia Development Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pumei Town\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Yunxiao County\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>363300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-21-53\u003C\u002Fp>\n\n\u003Cp>August 4, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Wong,\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, BBC Group Limited, FEI 3010165327, at Yangxia Development Zone, Pumei Town, Yunxiao County, Zhangzhou, China, from March 22 to March 26, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, your firm manufactures L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products that are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and are misbranded under sections 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We reviewed your April 13, 2021 response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) drug products, including alcohol-based hand sanitizers\u003Csup>\u003Cem>\u003Cstrong>[1]\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. During the inspection of your facility, our investigator attempted to review analytical data from your gas chromatograph (GC) supporting the release of drug products distributed to the United States. However, your firm stated that all testing data from 2018 to 2020 was lost approximately one month prior to the initiation of our inspection. The GC is used to analyze the identity and strength of active ingredients and impurities contained in your OTC drug products, as well as other critical parameters. According to firm management, the data is unrecoverable. While your firm retained a static copy of laboratory records for review (i.e., paper record), they were inadequate as they did not preserve the dynamic record format of the full chromatographs to support test results and they did not include system suitability documentation that are part of the complete, original record.\u003C\u002Fp>\n\n\u003Cp>Additionally, our investigator observed that the computerized system and software associated with your GC lacked restricted access. For example, your laboratory employees who used the GC to perform analyses of drug products all logged in as “System Administrator,” which does not require a password, and had full system administration rights. In addition, audit trails on your GC were not enabled.\u003C\u002Fp>\n\n\u003Cp>Furthermore, you did not retain all original, dynamic records, obtained during the course of testing on other laboratory equipment. Your viscometer and UV-Vis spectrophotometer had the capability to save data from product\u002Fmaterial testing. Despite having this capability, your analysts failed to save the complete, dynamic testing data, and therefore the data was not available for review by the FDA investigator. The viscometer is used to measure the viscosity of finished drug products during release testing and the UV-Vis spectrophotometer is used to measure ethanol content during raw material testing.\u003C\u002Fp>\n\n\u003Cp>Your firm also utilizes electronic spreadsheets to input data for your stability program. However, these spreadsheets are not controlled and there is no protection to prevent data manipulation, overwriting, or erasure.\u003C\u002Fp>\n\n\u003Cp>In your response, you indicated that you purchased and\u002For installed additional equipment to address this violation, including, but not limited to, an uninterrupted power source, remote hard drive, electrical equipment, and new software. Your response also states that you have updated and developed associated procedures, created individual accounts for all personnel that utilize laboratory equipment, and conducted accompanying trainings. However, your response is inadequate because it lacked supporting documentation, including evidence to support that the computer security controls were effective at preventing data and document manipulation. Additionally, you did not perform a retrospective risk assessment into how system vulnerabilities may have impacted data integrity.\u003C\u002Fp>\n\n\u003Cp>Your firm does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003Cbr>\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003Cbr>\n• A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed Corrective Action and Preventive Action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003Cbr>\n• A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory computer systems. This should include, but not be limited to:\u003Cbr>\n&nbsp; &nbsp; o A list of all hardware that includes all equipment, both standalone and network, in your laboratory.\u003Cbr>\n&nbsp; &nbsp; o Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems.\u003Cbr>\n&nbsp; &nbsp; o A list of all software configurations and versions, details of all user privileges, and oversight responsibilities for each of your laboratory systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory computer systems, and their organizational affiliations and titles. Also describe how you will ensure laboratory staff are not given administrative rights, or other permissions that compromise data retention or reliability.\u003Cbr>\n&nbsp; &nbsp; o System security provisions, including, but not limited to, whether unique user names\u002Fpasswords are always used, and their confidentiality safeguarded.\u003Cbr>\n&nbsp; &nbsp; o Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\u003Cbr>\n&nbsp; &nbsp; o Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\u003Cbr>\n&nbsp; &nbsp; o A detailed summary of your procedural updates and associated training, including but not limited to system security control to prevent unauthorized access, appropriate user role assignments, secondary review of all analyses, and other system controls.\u003Cbr>\n&nbsp; &nbsp; o Provisions for oversight by QA managers, executives, and internal auditors with appropriate information technology (IT) expertise (e.g., to evaluate infrastructure, configuration, network requirements, data management practices, and segregation of duties including administrator rights).\u003Cbr>\n&nbsp; &nbsp; o A remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Include a full CAPA plan and any improvements made to date.\u003Cbr>\n&nbsp; &nbsp; o An independent, thorough retrospective assessment into the impact of laboratory system design, control, and staff practices on your data accuracy, completeness, and retention since January 1, 2018.\u003Cbr>\n• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your analytical test methods were not adequately validated, including those for the active ingredient ethanol, which is used to manufacture your alcohol-based hand sanitizers, and analysis for the impurity \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Specifically, no system suitability requirements were present and reference standards were not identified. Data must be available to establish that the analytical procedures used in testing meet proper standards of accuracy, sensitivity, specificity, and reproducibility and are suitable for their intended purpose.\u003Cbr>\n\u003Cbr>\nIn your response, you indicated that you updated test methods, established method validation protocols, and completed test method evaluation. However, your response is inadequate for the following reasons.\u003Cbr>\n• The response lacked information on the analyte reference standards used for the method validation.\u003Cbr>\n• The response lacked method validation details on identity of the tested analytes, system suitability, method specificity data, preparations of the analyte stock solutions, and accuracy and precision data from spike and recovery experiments at different concentration levels.\u003Cbr>\n• The response lacked an assessment of drug products manufactured utilizing the deficient methods.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003Cbr>\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n• An independent assessment of all test methods and data review procedures used by your firm to ensure they have appropriate instructions, method suitability criteria, and validation to determine whether they are fit for intended purposes.\u003Cbr>\n• Your test results, using an adequately validated test method, of retains for all finished drug products, within expiry. You should test all appropriate quality attributes of each batch that you distributed into U.S. commerce to ensure that your drug products conform to appropriate standards of identity, strength, quality, and purity. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Analytical Procedures and Methods Validation for Drugs and Biologics\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of method validation at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F87801\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F87801\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During our inspection, the investigator observed rust on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and product contact surfaces of four of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to manufacture drug products, including the manufacture of your OTC hand sanitizers. Upon request, you provided our investigator with manufacturing equipment maintenance logs for the aforementioned \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These documents were only available in Chinese. After the conclusion of the inspection, the FDA had the document translated and found that the document provided was for equipment identified as “liquid washing pan” with serial number WJB-001, which is located in Workshop \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> floor, and not the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with equipment ID’s 12 through 15 located in Workshop \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> floor that were observed with rust. FDA is concerned that you provided maintence records for different equipment than those requested during the inspection.\u003C\u002Fp>\n\n\u003Cp>In your response, you indicated that you replaced all the \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your response failed to address the rust documented in other parts of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, your response is inadequate as you failed to revise your cleaning and maintenance procedures to prevent recurrence of this issue, you failed to perform a risk assessment of drug products manufactured in the four \u003Cstrong>(b)(4)\u003C\u002Fstrong> that contained rust, and you did not determine the root cause of why employees who perform \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspections of manufacturing equipment did not observe the rust in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003Cbr>\n• Your plan for continued manufacture of drug products in the aforementioned \u003Cstrong>(b)(4)\u003C\u002Fstrong> containing rust. Our inspection observed rust on and around the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and other parts of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\n• A risk assessment for drug products manufactured in the four \u003Cstrong>(b)(4)\u003C\u002Fstrong> that contained rust to determine if a market action is warranted.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as a consumer topical antiseptic.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER product label and labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“HAND SANTIZER. . .\u003Cstrong>Drug Facts\u003C\u002Fstrong>. . .\u003Cstrong>Uses\u003C\u002Fstrong>. . . to decrease bacteria on the skin that could cause disease. . . \u003Cstrong>Direction\u003C\u002Fstrong> – rub a dime sized drop into hands.”\u003C\u002Fp>\n\n\u003Cp>This topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under Section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or other exemptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER drug products are GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products have been the subject of rulemaking under FDA’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use in a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act, addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products contain the active ingredient “chloroxylenol 0.015%.” Chloroxylenol is not permitted as an active ingredient for use as a consumer antiseptic hand rub drug product under the 1994 TFM.\u003Csup>\u003Cem>\u003Cstrong>[2]\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such products do not conform with the TFM, nor are they consistent with the formulations described in FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>[3]\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, CHERRY) SCENTED HAND SANITIZER products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Disparities in Records Submitted to the Agency\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on September 30, 2020 as information you provided in your response to a FDA request for records pursuant to section 704(a)(4) of the FD&amp;C Act, 21 U.S.C. 374(a)(4), did not appear to conform to CGMP. Specifically, your response to the FDA records request demonstrated a lack of analytical data supporting drug product release, as required under 21 CFR 211.165. Subsequent to your placement on Import Alert, you submitted additional data to the agency, now including test results of drug products you distributed to the United States. To evaluate the disparity in the records provided, and in part to evaluate if your firm should be removed from import alert, FDA conducted an inspection of your facility. However, upon physical inspection of your facility, the raw data related to your submitted test results were unavailable. The records you submitted electronically prior to the inspection were not consistent with what was observed during the FDA inspection of your facility. Your firm will remain on import alert until FDA is satisfied that the appearance of violations observed have been resolved.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility\u002Fin connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on September 23, 2020.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP.We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at BBC Group Limited, FEI 3010165327, at Yangxia Development Zone; Pumei Town, Yunxiao County; Zhangzhou, China into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3010165327 and ATTN: CDR Frank Verni.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nCC:\u003Cbr>\nMr. Richard Pecora, Consultant\u003Cbr>\nPecora Consulting LLC\u003Cbr>\n51 Sunnywood Drive\u003Cbr>\nWestfield, NJ 07090\u003Cbr>\npecoraconsulting@verizon.net\u003C\u002Fp>\n\n\u003Cp>________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rubs) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Are view of the purported formulations on the drug product’s labeling indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic handwashes and healthcare personnel handwashes an alcohol concentration of 60 to 95% by volume in an aqueous solution denatured in accordance with Bureau of Alcohol, Tobacco and Firearms regulations. 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products are not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Alan Wong\n\nRecipient Title\n\nGeneral Manager\n\nBBC Group Limited\n\nYangxia Development Zone\n\nPumei Town\n\nYunxiao County\n\n363300\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research\n\nUnited States\n\nWarning Letter 320-21-53\n\nAugust 4, 2021\n\nDear Mr. Wong,\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, BBC Group Limited, FEI 3010165327, at Yangxia Development Zone, Pumei Town, Yunxiao County, Zhangzhou, China, from March 22 to March 26, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, your firm manufactures L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products that are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and are misbranded under sections 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nWe reviewed your April 13, 2021 response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\nCGMP Violations\n\n1. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\n\nYour firm manufactures over-the-counter (OTC) drug products, including alcohol-based hand sanitizers[1]. During the inspection of your facility, our investigator attempted to review analytical data from your gas chromatograph (GC) supporting the release of drug products distributed to the United States. However, your firm stated that all testing data from 2018 to 2020 was lost approximately one month prior to the initiation of our inspection. The GC is used to analyze the identity and strength of active ingredients and impurities contained in your OTC drug products, as well as other critical parameters. According to firm management, the data is unrecoverable. While your firm retained a static copy of laboratory records for review (i.e., paper record), they were inadequate as they did not preserve the dynamic record format of the full chromatographs to support test results and they did not include system suitability documentation that are part of the complete, original record.\n\nAdditionally, our investigator observed that the computerized system and software associated with your GC lacked restricted access. For example, your laboratory employees who used the GC to perform analyses of drug products all logged in as “System Administrator,” which does not require a password, and had full system administration rights. In addition, audit trails on your GC were not enabled.\n\nFurthermore, you did not retain all original, dynamic records, obtained during the course of testing on other laboratory equipment. Your viscometer and UV-Vis spectrophotometer had the capability to save data from product\u002Fmaterial testing. Despite having this capability, your analysts failed to save the complete, dynamic testing data, and therefore the data was not available for review by the FDA investigator. The viscometer is used to measure the viscosity of finished drug products during release testing and the UV-Vis spectrophotometer is used to measure ethanol content during raw material testing.\n\nYour firm also utilizes electronic spreadsheets to input data for your stability program. However, these spreadsheets are not controlled and there is no protection to prevent data manipulation, overwriting, or erasure.\n\nIn your response, you indicated that you purchased and\u002For installed additional equipment to address this violation, including, but not limited to, an uninterrupted power source, remote hard drive, electrical equipment, and new software. Your response also states that you have updated and developed associated procedures, created individual accounts for all personnel that utilize laboratory equipment, and conducted accompanying trainings. However, your response is inadequate because it lacked supporting documentation, including evidence to support that the computer security controls were effective at preventing data and document manipulation. Additionally, you did not perform a retrospective risk assessment into how system vulnerabilities may have impacted data integrity.\n\nYour firm does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload.\n\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide the following:\n\n• A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n• A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed Corrective Action and Preventive Action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\n• A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory computer systems. This should include, but not be limited to:\n\no A list of all hardware that includes all equipment, both standalone and network, in your laboratory.\n\no Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems.\n\no A list of all software configurations and versions, details of all user privileges, and oversight responsibilities for each of your laboratory systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory computer systems, and their organizational affiliations and titles. Also describe how you will ensure laboratory staff are not given administrative rights, or other permissions that compromise data retention or reliability.\n\no System security provisions, including, but not limited to, whether unique user names\u002Fpasswords are always used, and their confidentiality safeguarded.\n\no Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\n\no Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\n\no A detailed summary of your procedural updates and associated training, including but not limited to system security control to prevent unauthorized access, appropriate user role assignments, secondary review of all analyses, and other system controls.\n\no Provisions for oversight by QA managers, executives, and internal auditors with appropriate information technology (IT) expertise (e.g., to evaluate infrastructure, configuration, network requirements, data management practices, and segregation of duties including administrator rights).\n\no A remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Include a full CAPA plan and any improvements made to date.\n\no An independent, thorough retrospective assessment into the impact of laboratory system design, control, and staff practices on your data accuracy, completeness, and retention since January 1, 2018.\n\n• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit. Your change management program should also include provisions for determining change effectiveness.\n\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nYour analytical test methods were not adequately validated, including those for the active ingredient ethanol, which is used to manufacture your alcohol-based hand sanitizers, and analysis for the impurity (b)(4). Specifically, no system suitability requirements were present and reference standards were not identified. Data must be available to establish that the analytical procedures used in testing meet proper standards of accuracy, sensitivity, specificity, and reproducibility and are suitable for their intended purpose.\n\nIn your response, you indicated that you updated test methods, established method validation protocols, and completed test method evaluation. However, your response is inadequate for the following reasons.\n\n• The response lacked information on the analyte reference standards used for the method validation.\n\n• The response lacked method validation details on identity of the tested analytes, system suitability, method specificity data, preparations of the analyte stock solutions, and accuracy and precision data from spike and recovery experiments at different concentration levels.\n\n• The response lacked an assessment of drug products manufactured utilizing the deficient methods.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• An independent assessment of all test methods and data review procedures used by your firm to ensure they have appropriate instructions, method suitability criteria, and validation to determine whether they are fit for intended purposes.\n\n• Your test results, using an adequately validated test method, of retains for all finished drug products, within expiry. You should test all appropriate quality attributes of each batch that you distributed into U.S. commerce to ensure that your drug products conform to appropriate standards of identity, strength, quality, and purity. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\n\nSee FDA’s guidance document Analytical Procedures and Methods Validation for Drugs and Biologics for general principles and approaches that FDA considers appropriate elements of method validation at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F87801\u002Fdownload.\n\n3. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\n\nDuring our inspection, the investigator observed rust on (b)(4) and product contact surfaces of four of the (b)(4) used to manufacture drug products, including the manufacture of your OTC hand sanitizers. Upon request, you provided our investigator with manufacturing equipment maintenance logs for the aforementioned (b)(4). These documents were only available in Chinese. After the conclusion of the inspection, the FDA had the document translated and found that the document provided was for equipment identified as “liquid washing pan” with serial number WJB-001, which is located in Workshop (b)(4) on the (b)(4) floor, and not the (b)(4) with equipment ID’s 12 through 15 located in Workshop (b)(4) on the (b)(4) floor that were observed with rust. FDA is concerned that you provided maintence records for different equipment than those requested during the inspection.\n\nIn your response, you indicated that you replaced all the (b)(4) in your (b)(4). However, your response failed to address the rust documented in other parts of the (b)(4). Additionally, your response is inadequate as you failed to revise your cleaning and maintenance procedures to prevent recurrence of this issue, you failed to perform a risk assessment of drug products manufactured in the four (b)(4) that contained rust, and you did not determine the root cause of why employees who perform (b)(4) inspections of manufacturing equipment did not observe the rust in the (b)(4).\n\nIn response to this letter, provide the following:\n\n• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\n• Your plan for continued manufacture of drug products in the aforementioned (b)(4) containing rust. Our inspection observed rust on and around the (b)(4) and other parts of the (b)(4).\n\n• A risk assessment for drug products manufactured in the four (b)(4) that contained rust to determine if a market action is warranted.\n\nUnapproved New Drug and Misbranding Violations\n\nL.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as a consumer topical antiseptic.\n\nExamples of claims observed on the L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER product label and labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\n“HAND SANTIZER. . .Drug Facts. . .Uses. . . to decrease bacteria on the skin that could cause disease. . . Direction – rub a dime sized drop into hands.”\n\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under Section 505G of the FD&C Act (which is not the case for this product, as further described below) or other exemptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER drug products are GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products have been the subject of rulemaking under FDA’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use in a consumer antiseptic rub.\n\nSection 505G of the FD&C Act, addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to the product label, L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products contain the active ingredient “chloroxylenol 0.015%.” Chloroxylenol is not permitted as an active ingredient for use as a consumer antiseptic hand rub drug product under the 1994 TFM.[2] Such products do not conform with the TFM, nor are they consistent with the formulations described in FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.[3]\n\nAdditionally, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, CHERRY) SCENTED HAND SANITIZER products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nDisparities in Records Submitted to the Agency\n\nFDA placed your firm on Import Alert 66-40 on September 30, 2020 as information you provided in your response to a FDA request for records pursuant to section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4), did not appear to conform to CGMP. Specifically, your response to the FDA records request demonstrated a lack of analytical data supporting drug product release, as required under 21 CFR 211.165. Subsequent to your placement on Import Alert, you submitted additional data to the agency, now including test results of drug products you distributed to the United States. To evaluate the disparity in the records provided, and in part to evaluate if your firm should be removed from import alert, FDA conducted an inspection of your facility. However, upon physical inspection of your facility, the raw data related to your submitted test results were unavailable. The records you submitted electronically prior to the inspection were not consistent with what was observed during the FDA inspection of your facility. Your firm will remain on import alert until FDA is satisfied that the appearance of violations observed have been resolved.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility\u002Fin connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on September 23, 2020.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP.We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at BBC Group Limited, FEI 3010165327, at Yangxia Development Zone; Pumei Town, Yunxiao County; Zhangzhou, China into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3010165327 and ATTN: CDR Frank Verni.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nMr. Richard Pecora, Consultant\n\nPecora Consulting LLC\n\n51 Sunnywood Drive\n\nWestfield, NJ 07090\n\npecoraconsulting@verizon.net\n\n________________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rubs) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Are view of the purported formulations on the drug product’s labeling indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n2 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic handwashes and healthcare personnel handwashes an alcohol concentration of 60 to 95% by volume in an aqueous solution denatured in accordance with Bureau of Alcohol, Tobacco and Firearms regulations. 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n3 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because L.O.L. SURPRISE! (WATERMELON, STRAWBERRY, and CHERRY) SCENTED HAND SANITIZER products are not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.","BBC Group Limited","bbc-group-limited-614659-08042021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbbc-group-limited-614659-08042021","2026-10-26T08:08:01.938176+00:00","2021-08-10","614659","Mr. Alan Wong","2026-08-20T02:42:31.43+00:00","VIA UPS","2021-08-04",{"id":55,"raw":56,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":23,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":19,"issuing_office":60,"recipient_name":72,"body_fetched_at":73,"delivery_method":74,"recipient_title":19,"reference_number":19,"action_taken_date":75,"medical_device_id":19,"response_letter_date":19},3520,[57,58,59,60,61,13,13,13],"\u003Ctime datetime=\"2021-02-19T17:00:00Z\">02\u002F19\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-18T05:00:00Z\">02\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsana-group-llc-612256-02182021\">SANA Group LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jason W. Harris\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>SANA Group LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1200 E. Woodhurst S-200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Springfield\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>65804\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>RE: [CMS:612256]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Dear Mr. Harris,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.sleepsana.com\u003Cspan>, \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>in December 2020 and has determined that you take orders there for your Sleep Sana “Sleep Drops” and “Sleep Shots” products. The claims on your website establish that your \u003Cspan>products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fhome\">\u003Cspan>\u003Cspan>www.fda.gov\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Examples of some of the\u003C\u002Fspan> \u003Cspan>website claims that provide evidence that your “Sleep Drops” and “Sleep Shots” are intended for use as drugs include:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>On the webpage for Sleep Sana “Sleep Drops” and “Sleep Shots” ingredients: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"GABA (an ingredient in your \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>Sleep Sana “Sleep Drops” and “Sleep Shots” products)\u003C\u002Fspan>\u003Cspan>\u003Cspan> is taken by mouth for relieving anxiety, ... and treating attention deficit hyperactivity disorder (ADHD). It is also used for ... stabilizing blood pressure, and relieving pain.\" \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"L-tryptophan (an ingredient in your \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>Sleep Sana “Sleep Drops” and “Sleep Shots” products)\u003C\u002Fspan>\u003Cspan>\u003Cspan> is used for insomnia, sleep apnea, depression, anxiety, facial pain, a severe form of premenstrual syndrome called premenstrual dysphoric disorder (PMDD), ... attention deficit-hyperactivity disorder (ADHD), Tourette's syndrome....\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\"\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>&nbsp;\"Valerian (an ingredient in your \u003C\u002Fspan>\u003Cspan>Sleep Sana “Sleep Drops” and “Sleep Shots” products)\u003C\u002Fspan>\u003Cspan> is most commonly used for sleep disorders, especially the inability to sleep (insomnia).\" \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\"[Y]our body may produce melatonin (an ingredient in your \u003C\u002Fspan>\u003Cspan>Sleep Sana “Sleep Drops” and “Sleep Shots” products)\u003C\u002Fspan>\u003Cspan> either earlier or later in the day than usual. This change can lead to symptoms of seasonal affective disorder (SAD), or winter depression.\"\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your “Sleep Drops” and “Sleep Shots” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. \u003Cspan>§§ \u003C\u002Fspan>331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. \u003Cspan>§ \u003C\u002Fspan>201.5).&nbsp; Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your “Sleep Drops” and “Sleep Shots” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for their intended purposes. Accordingly, your “Sleep Drops” and “Sleep Shots” products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. \u003Cspan>§ \u003C\u002Fspan>352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. \u003Cspan>§\u003C\u002Fspan> 331(a)]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You should take prompt action to address the violates cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps that you have taken to address these violations.&nbsp; Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation.&nbsp; If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. Your reply should be sent via e-mail to \u003C\u002Fspan>\u003Ca href=\"mailto:FDAAdvisory@fda.hhs.gov\">\u003Cspan>FDAAdvisory@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u002FS\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>William A. Correll Jr.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Center for Food Safety and Applied Nutrition\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Food and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJason W. Harris\n\nRecipient Title\n\nOwner\n\nSANA Group LLC\n\n1200 E. Woodhurst S-200\n\nSpringfield, MO 65804\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nRE: [CMS:612256]\n\nDear Mr. Harris,\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.sleepsana.com, in December 2020 and has determined that you take orders there for your Sleep Sana “Sleep Drops” and “Sleep Shots” products. The claims on your website establish that your products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your “Sleep Drops” and “Sleep Shots” are intended for use as drugs include:\n\nOn the webpage for Sleep Sana “Sleep Drops” and “Sleep Shots” ingredients:\n\n\"GABA (an ingredient in your Sleep Sana “Sleep Drops” and “Sleep Shots” products) is taken by mouth for relieving anxiety, ... and treating attention deficit hyperactivity disorder (ADHD). It is also used for ... stabilizing blood pressure, and relieving pain.\"\n\n\"L-tryptophan (an ingredient in your Sleep Sana “Sleep Drops” and “Sleep Shots” products) is used for insomnia, sleep apnea, depression, anxiety, facial pain, a severe form of premenstrual syndrome called premenstrual dysphoric disorder (PMDD), ... attention deficit-hyperactivity disorder (ADHD), Tourette's syndrome....\"\n\n\"Valerian (an ingredient in your Sleep Sana “Sleep Drops” and “Sleep Shots” products) is most commonly used for sleep disorders, especially the inability to sleep (insomnia).\"\n\n\"[Y]our body may produce melatonin (an ingredient in your Sleep Sana “Sleep Drops” and “Sleep Shots” products) either earlier or later in the day than usual. This change can lead to symptoms of seasonal affective disorder (SAD), or winter depression.\"\n\nYour “Sleep Drops” and “Sleep Shots” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour “Sleep Drops” and “Sleep Shots” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for their intended purposes. Accordingly, your “Sleep Drops” and “Sleep Shots” products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address the violates cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps that you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. Your reply should be sent via e-mail to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam A. Correll Jr.\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration","SANA Group LLC","sana-group-llc-612256-02182021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsana-group-llc-612256-02182021","2026-10-26T08:09:53.390359+00:00","2021-02-19","612256","Food & Beverages","Jason W. Harris","2026-08-20T03:22:28.818+00:00","Via Overnight Delivery","2021-02-18",{"id":77,"raw":78,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":88,"fei_number":19,"letter_url":89,"updated_at":90,"action_type":22,"case_status":23,"posted_date":91,"marcs_cms_no":92,"product_type":71,"closeout_date":19,"issuing_office":82,"recipient_name":93,"body_fetched_at":94,"delivery_method":95,"recipient_title":19,"reference_number":19,"action_taken_date":96,"medical_device_id":19,"response_letter_date":19},97,[79,80,81,82,83,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-08T04:00:00Z\">06\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fys-group-inc-731129-06082026\">YS Group Inc.\u003C\u002Fa>","Office of Inspections and Investigations","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Yamato Miura, Co-Chief Executive Officer and Chief Financial Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Steve Tieu, Co-Chief Executive Officer and Secretary \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>YS Group Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1108 S Baldwin Ave Suite B6\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Arcadia\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91007\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS #731129\u003C\u002Fp>\u003Cp>Dear Mr. Miura and Mr. Tieu:\u003C\u002Fp>\u003Cp>On April 30, 2026 through May 12, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of YS Group Inc. located at 1108 S Baldwin Ave Suite B6, Arcadia, CA 91007. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import.\u003C\u002Fp>\u003Cp>Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\u003Cp>We acknowledge receipt of your response dated June 2, 2026 in which you stated you developed the hazard analysis for the tofu skin imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> and requested \u003Cstrong>(b)(4)\u003C\u002Fstrong> to provide a certificate of analysis for future shipments of tofu skin as documentation of your verification activity. You also clarified that the foreign supplier of the buckwheat flour listed on the Form FDA 483a was a distributor and you will update your database to the correct manufacturer. You included the hazard analysis for tofu skin imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> with the response. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>Tofu Skin imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Dried Seaweed imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Buckwheat Flour imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During our inspection you provided the following:\u003C\u002Fp>\u003Cul>\u003Cli>Supplier HACCP Verification Records for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>HACCP plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>You stated that you are not familiar with FSVP requirements and have just recently started to conduct and document FSVP activities. However, it is not clear how these documents would apply to your FSVP program as the HACCP records are for fish and fishery products, and you did not explain how they would apply to your FSVP program.\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the food from the identified foreign supplier on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Lydia Chan, Compliance Officer, 1201 Harbor Bay Parkway, Alameda, CA 94502. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Lydia Chan via email at lydia.chan@fda.hhs.gov. Please reference CMS #731129 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Dr. Kathleen Turner\u003Cbr>Program Division Director\u003Cbr>Division of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nYamato Miura, Co-Chief Executive Officer and Chief Financial Officer\n\nRecipient Title\n\nSteve Tieu, Co-Chief Executive Officer and Secretary\n\nYS Group Inc.\n\n1108 S Baldwin Ave Suite B6\n\nArcadia, CA 91007\n\nUnited States\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nJune 8, 2026\nWARNING LETTER\nRe: CMS #731129\nDear Mr. Miura and Mr. Tieu:\nOn April 30, 2026 through May 12, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of YS Group Inc. located at 1108 S Baldwin Ave Suite B6, Arcadia, CA 91007. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import.\nBecause of these significant violations, you are not in compliance with section 805 of the FD&C Act.\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\nWe acknowledge receipt of your response dated June 2, 2026 in which you stated you developed the hazard analysis for the tofu skin imported from (b)(4) and requested (b)(4) to provide a certificate of analysis for future shipments of tofu skin as documentation of your verification activity. You also clarified that the foreign supplier of the buckwheat flour listed on the Form FDA 483a was a distributor and you will update your database to the correct manufacturer. You included the hazard analysis for tofu skin imported from (b)(4) with the response. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\nTofu Skin imported from (b)(4)\nDried Seaweed imported from (b)(4)\nBuckwheat Flour imported from (b)(4)\nDuring our inspection you provided the following:\nSupplier HACCP Verification Records for (b)(4), and (b)(4)\nHACCP plan for (b)(4)\nYou stated that you are not familiar with FSVP requirements and have just recently started to conduct and document FSVP activities. However, it is not clear how these documents would apply to your FSVP program as the HACCP records are for fish and fishery products, and you did not explain how they would apply to your FSVP program.\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the food from the identified foreign supplier on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Lydia Chan, Compliance Officer, 1201 Harbor Bay Parkway, Alameda, CA 94502. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Lydia Chan via email at lydia.chan@fda.hhs.gov. Please reference CMS #731129 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nDr. Kathleen Turner\nProgram Division Director\nDivision of West Coast Imports","YS Group Inc.","ys-group-inc-731129-06082026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fys-group-inc-731129-06082026","2026-10-26T08:10:37.57101+00:00","2026-06-16","731129","Yamato Miura, Co-Chief Executive Officer and Chief Financial Officer","2026-08-19T04:37:08.527+00:00","Via Express Delivery","2026-06-08",4,{"510k":99,"classification":100,"enforcement":101,"event":102,"event_backfill":103,"pma":104,"warning_letter":105},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]